Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 1:46 AM
Ignite Modification Date: 2025-12-26 @ 12:05 AM
NCT ID: NCT02253394
Description: None
Frequency Threshold: 0
Time Frame: 2 years
Study: NCT02253394
Study Brief: The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
AMB + Spiro, Cardiopulmonary Fitness Ambrisentan 5 or 10 mg every day (QD) Spironolactone 50 mg QD Ambrisentan plus Spironolactone: Cardiopulmonary fitness 0 None 0 2 0 2 View
Placebo Cardiopulmonary Fitness Placebo mimics spironolactone 50 mg and will be taken QD Ambrisentan plus Placebo: Placebo is a sugar pill manufactured to resemble spironolactone 50 mg Cardiopulmonary fitness 0 None 0 2 0 2 View
Serious Events(If Any):
Other Events(If Any):